| Name | Title | Contact Details |
|---|---|---|
Johnny Chalcas |
Director Of Procurement | Profile |
Dudnyk Healthcare Group is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wexford Health Sources, Inc., a correctional health care company, provides health care programs for the corrections departments and/or human services agencies, as well as programs for jail clients in the United States. It offers medical services to implement and maintain a correctional health care delivery system that includes onsite care, offsite care, vision and hearing, infection control, durable medical equipment, medical recordkeeping, hospice and end-of-life, and re-entry and recidivism programs; laboratory, X-ray, and other diagnostic services; physical, occupational, and speech therapy services; and mobile surgery units, chemotherapy, specialized onsite diagnostic services, etc. The company also manages a range of behavioral health programs at various acuity levels, including outpatient, crisis stabilization and management, and acute psychiatric inpatient care. In addition, it offers mental health programs; detoxification program for inmates who are chemically dependent, intoxicated, or undergoing withdrawal upon entering a facility; substance abuse counseling services, including assessment and referral; individual and group counseling; therapeutic communities; and other treatment interventions. Further, the company provides psychologically based sex offender treatment program that includes assessment, treatment, and discharge planning; pharmacy and pharmaceutical consulting services, including the prescribing, dispensing, delivery, administration, management, and disposal of prescription and non-prescription medications; and rehabilitation, utilization management, and claims processing services to state, regional, and local clients. It manages health care programs for correctional facilities and other types of institutions, including prisons, juvenile detention centers, substance abuse facilities, mental health units, and sex offender treatment centers. Wexford Health Sources, Inc. was incorporated in 1992 and is based in Pittsburgh, Pennsylvania.
Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies and relieve administrative burdens, allowing them to focus on their core mission: delivering high-quality care. Accretive Health’s operational framework centers on demonstrated capabilities and proficiencies across the end-to-end revenue cycle. Our solutions translate proven tactics and processes into measurable impact, leading to superior financial and organizational outcomes. Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies and relieve administrative burdens, allowing them to focus on their core mission: delivering high-quality care. Accretive Health’s operational framework centers on demonstrated capabilities and proficiencies across the end-to-end revenue cycle. Our solutions translate proven tactics and processes into measurable impact, leading to superior financial and organizational outcomes.
Lexicon Pharmaceuticals, Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Spring, TX. To find more information about Lexicon Pharmaceuticals, Inc, please visit www.lexpharma.com
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.